News

Back to the list of news

April 9, 2014

Green Cross Sets up Shop in Montréal

Eager to break into the North American market, Korean company Green Cross, the global leader in biopharmaceuticals, has chosen Montréal over every other city on the continent as the site of a new blood plasma fractionation plant.

 

The agreement was signed on April 3 at Investissement Québec’s offices in the presence of Il-Sup Huh, Chairman and CEO of Green Cross, B.G. Rhee, President of Green Cross Holdings, Young Ho Kim, President and CEO of Green Cross Biotherapeutics, the new Québec subsidiary, and Mario Albert, President and CEO of Investissement Québec.

Photo of B.G. Rhee, President of the Green Cross Holdings Board of Directors, Mario Albert, President and CEO of Investissement Québec, Kim Young-ho, President of Green Cross Biotherapeutics, and Huh Il-su, President and CEO of Green Cross.

 

From left to right: B.G. Rhee, President of Green Cross Holdings, Mario Albert, President and CEO of Investissement Québec, Young Ho Kim, President and CEO of Green Cross Biotherapeutics, and Il-Sup Huh, Chairman and CEO of Green Cross.

 

Héma-Québec, a new partner for the Korean company, also took part in the signing ceremony.

 

The agreement comes hard on the heels of two major events that will strengthen and give new impetus to Québec-Korean relations. First, Investissement Québec opened an office in Seoul in December 2013, and second, a free-trade agreement between Canada and Korea was struck in March 2014, possibly taking effect as early as 2015.

 

Québec’s many competitive advantages make it an ideal location for Korean businesses to pursue a wide range of expansion projects. 

 

April 9, 2014

 

 

Share

Contact your expert

Benoît Larouche

Director, Business Development, New York

212 843-0976